Merz Pharma

Planatome Completes Spinout from Parent Company, Bolsters Executive Team with Key New Hires

Retrieved on: 
Tuesday, October 10, 2023
Patent, Silicon, Hospital, MBA, Veteran, Inflammation, Bachelor of Engineering, Modular Engine Management System, Johnson & Johnson, George Washington University, Robotics, Health, FDA, Trauma, Growth, Merz Pharma, Scar, Surgeon, Instrument, Patient, Pennsylvania State University, Troy University, Dentistry, Management, Engineering

The company also announced today that it has expanded its leadership team with the addition of two key industry executives.

Key Points: 
  • The company also announced today that it has expanded its leadership team with the addition of two key industry executives.
  • Surgeons using our blades have told us they see improved outcomes, setting a new standard of care as a result."
  • Currently in use by surgeons across the country, Planatome blades have proven to be a low-trauma, high-precision surgical tool.
  • To learn more about Planatome and its new hires, follow the company on LinkedIn: Planatome LinkedIn and Keith Jeffcoat and Steve Joachim .

Dermal Fillers Market to Surpass $9.13 Billion by 2028, Market Driven by Medical Tourism & Aesthetic Treatment - Arizton

Retrieved on: 
Tuesday, April 11, 2023
Collection, Travel, Medical tourism, Galderma, Ageing, Privacy, Cosmeceutical, Patient, Risk, Growth, Merz Pharma, Chin, FDA, Therapy, Filler (linguistics), Human, Pharmaceutical industry, Medical device, European

Download the Free Sample Report: https://www.arizton.com/request-sample/3771

Key Points: 
  • Download the Free Sample Report: https://www.arizton.com/request-sample/3771
    Over the last decade, the global dermal fillers market has witnessed the launch of advanced products and innovative non-invasive procedures.
  • In 2020, TEOXANE signed a distribution agreement with Revance Therapeutics to distribute the US's RHA Collection of dermal fillers.
  • Moreover, medical tourism provides access to a wider range of dermal fillers and related treatments for cost-effectiveness, convenience, and access to quality medical care.
  • Therefore, medical tourism is providing a better opportunity for vendors of dermal fillers in many ways.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Monday, December 5, 2022
Class Action Lawsuit, Professional Services, Legal, Summons, Court order, Forest Laboratories, Hearing, District court, Teva, Sun Pharma, AB, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Generic, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Court, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Indian Residential Schools Settlement Agreement, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Monday, December 5, 2022
Summons, Court order, Settlement, Court, Forest Laboratories, Hearing, District court, Teva, Plaintiff, Sun Pharma, AB, Alzheimer's disease, Merz, Upsher-Smith Laboratories, TPP Nikola Tesla, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Person, Comment, Partnership, Merz Pharma, Actavis, Laboratory, Tablet, Tobacco Master Settlement Agreement, Inwood Laboratories, Inc. v. Ives Laboratories, Inc., Wockhardt, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023,or request to be excluded from the class by February 3, 2023.

Miller Law LLC and Safirstein Law LLC Announce Proposed Settlements in the Namenda Indirect Purchaser Antitrust Litigation

Retrieved on: 
Thursday, December 1, 2022
Class Action Lawsuit, Professional Services, Legal, Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc., Upsher-Smith Laboratories, Comment, Merz Pharma, Tablet, Court order, Generic, AB, Indian Residential Schools Settlement Agreement, Merz, Actavis, Sun Pharma, TPP Nikola Tesla, District court, Summons, Teva, Partnership, Court, Laboratory, Person, Forest Laboratories, Hearing, Generic drug, Insurance, Life insurance, Memantine

The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).

Key Points: 
  • The proposed settlement with the Generic Defendants includes both consumers and third-party payors (entities such as employers or insurers with self-funded prescription drug plans).
  • The settlement with Teva includes the AB-rated generic versions of Namenda IR 5 or 10 mg tablets.
  • If you are a member of one or both classes, you may comment on or object to the proposed settlements.
  • You must object to the settlements by February 3, 2023, or request to be excluded from the class by February 3, 2023.

$25+ Billion Antifungal Drugs Markets, 2030 by Drug Class, Infection Type, Therapeutic Indications, Dosage Forms - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 8, 2022
Health, General Health, Conditional sentence, Candidiasis, Polyene, Form, Dermatophytosis, CDC, Disease, Death, Incidence, Infection, Gilead Sciences, Skin, Merz Pharma, Bloodstream infections, Pfizer, Mycosis, Center, Azole, Prevalence, CAGR, Population, Immunodeficiency, Centers for Disease Control and Prevention, Bayer, Echinocandin, Johnson & Johnson, Tuberculosis, Abbott Laboratories, Diabetes, Blastomycosis, Growth, Drug development, Region, Environment, Patient, Pharmaceutical industry, Fine chemical, Aspergillosis

The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antifungal Drugs Market By Drug Class, By Infection Type, By Therapeutic Indications, By Dosage Forms: Global Opportunity Analysis and Industry Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anti-fungal drugs market was valued at $16,572.1 million in 2020, and is estimated to reach $25,045.20 million by 2030, growing at a CAGR of 3.9% from 2021 to 2030.
  • Moreover, the key players Pfizer Inc., Abbott Laboratories, and Bayer Ag provide numerous anti-fungal drugs that contribute toward the market growth.
  • The antifungal drugs market is segmented on the basis of drug type, therapeutic indication, infection type, and region.

Insights on the Cosmetic Surgery Global Market to 2027 - Size, Trends & Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, July 25, 2022
Surgery, Health, Other Health, SWOT, Gender, Cleveland Clinic, Industry, Johnson & Johnson, Procedure, Research, Allergan, Inc., Merz Pharma, Review, Long Island Plastic Surgical Group, P.C, Bausch Health, Galderma, Porter's five forces analysis, Genesis, Retail

The "Global Cosmetic Surgery Market Size, Trends & Growth Opportunity, By Procedure, By End-User, By Gender, and Forecast till 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cosmetic Surgery Market Size, Trends & Growth Opportunity, By Procedure, By End-User, By Gender, and Forecast till 2027" report has been added to ResearchAndMarkets.com's offering.
  • The Global Cosmetic Surgery Market research study includes a forecast, share, size, and dynamics analysis.
  • The Global Cosmetic Surgery Market has been evaluated for the forecast period using Porter's Five Force Model for the review period of 2020 to 2027.
  • The study examines Global Cosmetic Surgery Market drivers and restraints, as well as their impact on demand, throughout the forecast period.

Merz Aesthetics presents data at the IMCAS World Congress 2022

Retrieved on: 
Friday, June 3, 2022
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Science, Microparticle, Congress, Gesellschaft mit beschränkter Haftung, Program, Research, Doctor of Philosophy, CEST, Aesthetics, File association, Hyaluronic acid, 2021 Essex County Council election, MD–PhD, Patient, Toxin (comics), EMEA, Safety, Uniqueness, Skin care, Merz Pharma, World Congress, Cadaver, Merz Aesthetics Women's Challenger, Family, View, Dermatology, Ageing, Pharmaceutical industry, Industrial design, Medical device, Online gambling, MD

Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base.

Key Points: 
  • Merz Aesthetics today confirmed its commitment as a global leader in medical aesthetics at the 2022 International Master Course on Aging Science (IMCAS) World Congress, with the presentation of data from its medical aesthetics portfolio and a clear focus on addressing the aesthetic needs of a diversifying society and a younger patient base.
  • Merz Aesthetics is organizing a program led by esteemed medical aesthetic experts, participating in various IMCAS sessions and presenting new data throughout the course of the meeting.
  • Merz Aesthetics is part of Merz Group, a family-owned business founded in 1908 and based in Frankfurt, Germany.
  • MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.

Global Cosmetic Surgery and Procedure Market (2022 to 2030) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 2, 2022
Technology, Cosmetics, Men, Retail, Chemicals, Plastics, Health, Manufacturing, Consumer, Other Health, Pharmaceutical, Luxury, Surgery, Other Technology, Women, People, Woman, Man, Medical tourism, Johnson & Johnson, Laser, Chapter Three, Awareness, Travel, Chapter Five, Chapter Four, Procedure, Growth, Patient, Risk, Lists of countries and territories, Adoption, Merz Pharma, Social media, Surgeon, Safety, Dentistry, Health insurance, Ipsen, Nestlé

Furthermore, risk associated with cosmetic surgery has decreased due to technological developments and the presence of skilled surgeons.

Key Points: 
  • Furthermore, risk associated with cosmetic surgery has decreased due to technological developments and the presence of skilled surgeons.
  • It was observed that the volume of both surgical and nonsurgical cosmetic procedures has increased in the past few years.
  • Cosmetic Surgery & Procedure Market: Segment Analysis, By Procedure Type, 2018-2030 (USD Million)
    Chapter 5.
  • Cosmetic Surgery & Procedure Market: Regional Market Analysis, By Region, 2018-2030 (USD Million)
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005583/en/

Alzheimer's Disease Treatment Global Market Report 2022 Featuring Major Players - Allergan, Eisai, Novartis, Pfizer, Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche - ResearchAndMarkets.com

Retrieved on: 
Monday, May 30, 2022
Health, Biotechnology, Dementia, Acetylcholine, Memantine, Disease, Amnesia, Antibody, AC, Cholinesterase, Investment, Acetylcholinesterase, BACE, Government, Novartis, Therapy, Merz Pharma, Association, Allergan, Alzheimer's Association, Cholinesterase inhibitor, Neurological disorder, Thought, AD, Social skills, Pfizer, BACE1, VTV, NMDA, Geriatrics, Neurology, Growth, Prevalence, Diagnosis, AstraZeneca, Medical device, Residential care, Pharmaceutical industry, Medical imaging, Alzheimer's disease

Major players in the alzheimer's disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd.

Key Points: 
  • Major players in the alzheimer's disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca and F. Hoffmann-La Roche Ltd.
  • The global alzheimer's disease treatment market consists of sales of drugs used to treat Alzheimer's disease.
  • Therefore, the increasing prevalence of Alzheimer's disease is expected to drive the growth of the global Alzheimer's disease treatment market.
  • Lack of techniques for diagnosing Alzheimer's disease (AD) is expected to limit the growth of the global Alzheimer's disease treatment market.